
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is experiencing a positive outlook due to its recent market exclusivity announcement for Papzimeos in treating adult RRP, continued progress on its AdenoVerse portfolio, and the potential for label expansion opportunities. Additionally, the company's ongoing clinical trials and increasing patient enrollment numbers in its patient hub support a strong commercial launch and potential revenue growth. Despite potential risks in the clinical, regulatory, partnership, financial, and intellectual property areas, Precigen's strong presence at medical meetings and dedication to driving awareness and education for Papzimeos give confidence in the potential for success in the market.
Bears say
Precigen is experiencing financial growth, as shown by their increasing sales projections and confidence in reaching cash flow breakeven by 2026. However, the company's current financial performance and future prospects are dependent on its ability to successfully develop and commercialize its gene therapy platforms, which could face potential regulatory challenges and competition from other companies. Additionally, the company still has a significant amount of debt and negative cash flow, which could impact their ability to fund their research and development efforts.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares